CXR.TO - Concordia International Corp.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of CXR.TO earnings conference call or presentation 14-Nov-18 1:30pm GMT

    Q3 2018 Concordia International Corp Earnings Call

  • PR Newswire

    Concordia International Corp. Announces Name Change to ADVANZ PHARMA Corp.

    It is expected that the limited voting shares of the Company will begin trading under the new name, and that the Company's stock symbol will change from CXR to ADVZ, on or about December 3, 2018. "This is an exciting period for ADVANZ PHARMA, our stakeholders, and all our employees across the globe," said Graeme Duncan, the Company's Chief Executive Officer. "This new corporate identity, and the accompanying rebranding that we are working on, will help define ADVANZ PHARMA as a global pharmaceutical company that is determined to help innovate, shape and grow the specialty, off-patent sector.

  • CNW Group

    Concordia International Corp. Announces Third Quarter 2018 Results

    MISSISSAUGA, ON , Nov. 14, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced its financial and operational results for the three and nine months ended September 30, 2018 . "Our third quarter results are consistent with our expectations," said Graeme Duncan , Chief Executive Officer of Concordia.

  • Analysts Estimate Concordia Healthcare (CXRXF) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Concordia Healthcare (CXRXF) to Report a Decline in Earnings: What to Look Out for

    Concordia Healthcare (CXRXF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CNW Group

    Concordia International Corp. Announces Release Date for Third Quarter 2018 Results

    MISSISSAUGA, ON , Oct. 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2018 financial results before market open on Wednesday, November 14, 2018 .

  • CNW Group

    Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors

    "We believe that Maurice's extensive experience in the European pharmaceutical market will support Concordia's focus to acquire targeted products and companies in our core and proximate markets, and expand our product portfolio," said Graeme Duncan , Chief Executive Officer of Concordia. Mr. Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries.